S&P 500
5.360,79 +13,80 (+0,26%) Nasdaq
17.192,53 +59,40 (+0,35%) NIKKEI 225
39.038,16 +354,23 (+0,92%) Dólar/Euro
1,0767 -0,0037 (-0,34%) Petróleo Brent
82,11 +2,49 (+3,13%) Bitcoin EUR
64.607,06 -159,89 (-0,25%)
Neuren Pharmaceuticals Limited (NURPF)
Neuren Pharmaceuticals Limited
697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 9092 0480
https://www.neurenpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 708,1k | N/A | N/A |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | N/A | N/A | N/A |
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | N/A | N/A | N/A |
| Mr. Gerry Zhao | Vice President of Corporate Development | N/A | N/A | N/A |
| Dr. Liza A. Squires M.D. | Chief Medical Officer | N/A | N/A | N/A |
Descripción
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Gobierno corporativo
El ISS Governance QualityScore de Neuren Pharmaceuticals Limited, a día 1 de junio de 2024, es 5. Las puntuaciones base son Auditoría: 9; Tablero: 7; Derechos de los accionistas: 1; Compensación: 5.
